Table 5

Clinical Outcomes at 30 Days in the RESPOND Extension Cohort (N = 50)

All-cause mortality0 (0)
 Cardiovascular mortality0 (0)
All stroke3 (6)
 Disabling stroke10 (2)
Major vascular complications1 (2)
 Access site related1 (2)
Life-threatening or disabling bleeding0 (0)
Acute kidney injury (stage 2 or 3)1 (2)
Myocardial infarction0 (0)
Repeat procedure for valve-related dysfunction0 (0)
Hospitalization for valve-related symptoms or CHF0 (0)
Prosthetic aortic valve malapposition0 (0)
Coronary obstruction (periprocedural)0 (0)
Cardiac tamponade (periprocedural)0 (0)
Prosthetic valve thrombosis0 (0)
Prosthetic valve endocarditis0 (0)
New onset atrial fibrillation or atrial flutter2 (4)
Permanent pacemaker implantation
 Among all patients (n = 50)9 (18)
 Among patients without pacemaker at baseline (n = 45)9 (20)

Values are n (%) and are binary rates among patients with sufficient clinical follow-up or death, or who had an adverse event.

Abbreviations as in Table 2.

  • Includes valve migration, valve embolization, ectopic valve deployment, or transcatheter aortic valve (TAV)-in-TAV deployment.